Eli Lilly’s new diabetes drug continues to show promise as an obesity treatment



Eli Lilly continues to work on commercializing its strong pipeline of innovations, which is a key reason CNBC Investing Club owns the shares.


cnbc Business

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button